Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
3,072 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05206357 | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | active not recruiting | Phase 1 | 17 | GenmabINDUSTRY | 14 | Sep 11, 2026 | clinicaltrials |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | terminated | Phase 3 | 739 | Merck Sharp & Dohme LLC |
| 19 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06046742 | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | active not recruiting | Phase 3 | 1,130 | Hoffmann-La RocheINDUSTRY | 21 | Sep 11, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT06535607 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors(eVOLVE-02) | recruiting | Phase 2 | 257 | AstraZenecaINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma(CEVOLUTION) | recruiting | Phase 3 | 380 | Hoffmann-La RocheINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | recruiting | Phase 3 | 570 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT03180268 | Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | recruiting | Phase 3 | 163 | NRG OncologyOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
| NCT04493853 | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency(CAPItello-281) | active not recruiting | Phase 3 | 1,012 | AstraZenecaINDUSTRY | 32 | Sep 10, 2026 | clinicaltrials |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT05438212 | Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | active not recruiting | Phase 3 | 237 | NRG OncologyOTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT06057038 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | active not recruiting | Phase 1 | 8 | GenmabINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06914128 | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 450 | BayerINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | recruiting | Phase 1 | 103 | GenmabINDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | recruiting | Phase 2 | 20 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07766018 | A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 70 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | active not recruiting | Phase 1 | 170 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoADAURA) | active not recruiting | Phase 3 | 358 | AstraZenecaINDUSTRY | 25 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | active not recruiting | Phase 1 | 60 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | terminated | Phase 1 | 23 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | active not recruiting | Phase 3 | 191 | GenmabINDUSTRY | 27 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors(TITER) | recruiting | Phase 1 | 77 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07387471 | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | active not recruiting | Phase 2 | 14 | AbbVieINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers(RAINFOL-09) | recruiting | Phase 2 | 160 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07689201 | A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | recruiting | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07695831 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors | recruiting | Phase 1 | 112 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT02794558 | Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas | completed | N/A | 91 | InSightecINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors(PIKASSO-01) | recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
Data updated 19 days agoSource updated unknownsource: clinicaltrials